Lapatinib for HER2 overexpressing breast cancer
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of lapatinib for the treatment of advanced or metastatic HER2- overexpressing breast cancer based upon a review of the manufacturer's submission to the National Institu...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
2009.
|
| Subjects: | |
| Online Access: | Get fulltext |